7:30-8:00 Registration/refreshments
8:00-8:10 OPENING
REMARKS: Michael Zanolli, MD
ORAL
SESSION I Basic Science Session (Grand Salon D): Moderated by Sewon Kang, MD
Sunscreen and
Photoprotection
8:10-8:20 Photostability as a novel key
safety parameter for modern sunscreening products. Maier H, Schauberger G,
Brunnhofer K, H`nigsmann H. Medical University of Vienna, Vienna, Austria.
8:20-8:22 Q & A
8:22-8:32 The ideal sunscreen – how should
it protect? – an in silico assessment of objectives, opportunities, regulations
and limitations. Osterwalder U, Herzog B. Ciba, Inc., Basel, Switzerland.
8:32-8:34 Q & A
8:34-8:44 Examination and recommendation
for solar simulators use for the determination of sunscreen UVA efficacy. Sayre
RM, Dowdy JC. Rapid Precision Testing Laboratories, Cordova, TN, USA.
8:44-8:46 Q & A
8:46-8:56 Examination of the inclusion of
visible wavelengths (400nm to 700nm) in photosafety testing. Teske S, Berg
J, Risk S, Sayre RM, Dowdy RM. Rapid Precision Testing Laboratories, Cordova, TN, and Hill Top Research, St. Petersburg, FL, USA.
8:56-8:58 Q & A
9:00-9:30 SPECIAL TOPICS:
“State of the art of
systemic photoprotection”. Professor Lesley E. Rhodes, MD, University of Manchester, Manchester, United Kingdom.
9:30-9:35 Q & A
9:35-10:05 SPECIAL TOPICS:
“The status of FDA
sunscreen monograph”. Professor Henry W. Lim, MD, Henry Ford Hospital, Detroit, MI, USA.
10:05-10:10 Q & A
10:10-10:20 BREAK FOR COFFEE
10:20-10:50 SPECIAL TOPICS:
“Photodynamic
Therapy: applications and innovations”. Elma Baron, MD, Case Western
University,
Cleveland, OH, USA.
10:50-10:55 Q&A
11:00-11:30 “Update on DNA repair liposomes”.
Daniel B. Yarosh, PhD, AGI Dermatics, Freeport, NY, USA.
11:30-11:35 Q & A
11:40-1:00 LUNCH
ORAL SESSION II –
Clinical session (Grand Salon D): Moderated by Michael Zanolli, MD and
Heidi Jacobe, MD
Phototherapy
1:00-1:10 *The efficacy of “high dose”
versus “medium dose” UVA1 phototherapy in severe atopic dermatitis may be
related to skin type. Pacifico A, Di Carlo A, Leone G. Gallicano
Institute, Rome, Italy.
1:10-1:12 Q & A
1:12-1:22 *Safety, efficacy and
adherence of acitretin combined with home phototherapy. Yentzer BA,
Yelverton CB, Pearce DJ, Camacho FT, Makhzoumi Z, Clark A, Boles A, Fleischer
AB Jr, Balkrishnan R, Feldman SR. Wake Forest University School of Medicine, Winston-Salem, NC, USA.
1:22-1:24 Q & A
1:24-1:34 Long term remissions of early
cutaneous T cell lymphoma induced by PUVA without maintenance PUVA therapy.
Bruce AT, Jones D, Anderson TF. University of Michigan, Ann Arbor, MI, USA.
1:34-1:36 Q & A
1:36-1:46 Leukocyte trafficking of
8-MOP treated leukocytes after photopheresis in humans. Just U, Grumbeck
E, Knobler R, Kosner G, Ivancic E, Greinix H, Becherer A, Trautinger F. University of Vienna, Vienna, Austria.
1:46-1:48 Q & A
1:48-1:58 *Photoadaption of
vitiliginous skin to UVB phototherapy. Hexsel CL, Mahmoud BH,
Mitchell D, Rivard J, Owen M, Lim HW, Hamzavi I. Henry Ford Hospital, Detroit, MI, USA.
1:58-2:00 Q & A
Vitamin D
2:00-2:10 *Vitamin D and nonmelanoma skin
cancer in a cohort of kidney transplant patients. Hexsel CL, Eide MJ
Johnson CC, Mahmoud BH, Krajenta R, Jacobsen G, Rao D, Lim HW, Hamzavi I. Henry Ford Hospital, Detroit, MI, USA.
2:10:-2:12 Q & A
2:12-3:12 GUEST SPEAKER: R. Rox
Anderson, MD
“Enigmas from
laser photomedicine”. Wellman Center for Photomedicine, Boston, MA, USA.
3:12-3:17 Q & A
3:17-3:30 BREAK FOR COFFEE
3:30-4:00 SPECIAL TOPICS:
“Phototherapy
mechanisms of action and applications for vitiligo”. Iltefat Hamzavi, MD, Henry Ford Hospital, Detroit, MI, USA.
Photobiology, Immunology
4:00-4:10 *Impact of long wavelength UVA
and visible light on melanocompetent skin. Mahmoud B, Hexsel C, Liu Y,
Kollias N, Lim H, Hamzavi I. Henry Ford Hospital, Detroit, MI, USA.
4:10-4:12 Q & A
4:12-4:22 *Effects of pimecrolimus vs
triamcinolone on skin Langerhans cells after simulated solar irradiation. Santo Domingo D, Hsia A, Martires K, Plotner A, Baron E. Case Western Reserve University, Cleveland, OH, USA.
4:22-4:24 Q & A
4:24-4:34 Pigment melanin scavenges
nitric oxide in vitro. Possible consequences for keloid formation in pigmented
skin. Menter JM, Eatman D, Bayorh M, Willis I. Morehouse School of Medicine, Atlanta, GA, USA.
4:34-4:36 Q & A
4:36-4:46 The distribution of the antioxidant ergothioneine receptor OCTN1 in skin and skin cells. Smiles
K, Damaghi N, Jurukovska N,
Markova N, Yarosh D. AGI
Dermatics, Freeport,
NY, USA.
4:46-4:48 Q & A
4:48-4:58 Localized
bullous solar vasculitis. Ho WL, O’Regan G, Treacy A, Gaynor GM, Murphy GM. Beaumont Hospital, Dublin, Ireland.
4:58-5:00 Q & A
5:00-5:15 ANNOUNCEMENT
OF “BEST PRESENTATION BY RESIDENT/FELLOW”
5:30-8:00 COCKTAIL/RECEPTION: In conjunction with the American Contact Dermatitis
Society
Jointly sponsored event with
